---
title: "Home Market Approval ≠ EU Readiness"
description: "FDA or NMPA approval doesn't mean EU readiness. Learn why home market success often leads to delays under EU MDR, and how to avoid them."
url: https://qbdgroup.com/zh-cn/downloads/home-market-approval-eu-readiness
type: "White paper"
language: zh-cn
published: 2026-04-15
author: "Petra De Geest & Anne-Sophie Grell"
category: "Regulatory Affairs"
publisher: "QbD Group"
citation: "QbD Group, \"Home Market Approval ≠ EU Readiness\", https://qbdgroup.com/zh-cn/downloads/home-market-approval-eu-readiness"
---
# Home Market Approval ≠ EU Readiness
> FDA or NMPA approval doesn't mean EU readiness. Learn why home market success often leads to delays under EU MDR, and how to avoid them.

## About this white paper

FDA or NMPA approval is a real milestone, but it doesn't automatically mean your device is ready for Europe. **The EU MDR operates on a fundamentally different model**, one where clinical evidence, intended purpose, risk management, and post-market obligations must form a single, coherent lifecycle narrative.

This whitepaper breaks down **the most common misalignments** non-EU manufacturers encounter when entering the European market: from clinical evidence gaps and classification differences to Notified Body dynamics and operational requirements. Written by regulatory and clinical experts at QbD Group, it is aimed at **MedTech and digital health companies** that have achieved home market approval and are now planning their EU entry strategy.

## What you'll learn

- Why **FDA or NMPA approval** does not automatically translate to EU readiness
- How **clinical evidence requirements** differ under EU MDR, including data transferability and PMCF
- Why **clinical strategy** is typically the primary bottleneck in EU market entry
- What **the role of Notified Bodies** means in practice: selection, timing, and common reasons for delays
- Which **operational requirements** are most often underestimated, from EUDAMED to UDI and Authorised Representative obligations
- What the **2025 MDR revision proposal** changes for global manufacturers
---
Source: https://qbdgroup.com/zh-cn/downloads/home-market-approval-eu-readiness — © QbD Group. Quote freely with attribution and a link back.